Introduction: Exenatide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA),
INTRODUCTION
Achieving and maintaining glycemic control is the primary goal in the management of type 2 diabetes mellitus (T2DM). Patients are encouraged to adopt a healthy diet and increase their exercise; however, for patients who do not achieve glycemic control following lifestyle changes, oral antidiabetic agents are typically prescribed. Therapy is initiated with metformin, and other agents are added to the treatment regimen as necessary, to achieve the desired level of glycemic control [1] . Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of glucose-lowering agents used in the treatment of T2DM. The addition of a GLP-1 RA is one of the recommended injectable approaches for patients who are inadequately controlled on metformin monotherapy [1] .
Exenatide is a GLP-1 RA approved for the management of glycemic control among individuals with T2DM and is currently marketed in two formulations: a solution for twice-daily injection providing either 5 or 10 lg of exenatide [exenatide twice daily (BID)] and a prolonged-release once weekly (QW) injection that provides 2 mg of exenatide (exenatide QW). The long-acting formulation contains the active ingredient of the original exenatide BID formulation dispersed in microspheres of medical-grade poly-(d,l-lactide-co-glycolide) in an aqueous formulation [2] . Exenatide BID was the first GLP-1 RA approved in the twice-daily formulation, and exenatide QW was the first GLP-1 RA approved in the once weekly setting [3] . Other GLP-1 RAs administered QW that have since been developed include albiglutide and dulaglutide, whereas liraglutide and lixisenatide are administered once daily (QD). Overall, there are now several GLP-1 RAs on the market, with different dosing, and some evidence suggestive of differences in potencies [4] [5] [6] . Exenatide QW is expected to be associated with greater adherence and compliance than daily dosing, which could in turn translate into increased efficacy. As such, a study that estimates the relative efficacy and tolerability of exenatide QW compared to the existing GLP-1 RAs that have been developed is needed and would be valuable to investigate.
The efficacy and tolerability of exenatide in its QW formulation has been demonstrated in randomized controlled trials (RCT) within the DURATION clinical trial program [7] [8] [9] [10] and real-world evidence studies [11] [12] [13] QW was directly compared to another GLP-1 RA [10] . In the DURATION-6 trial, the efficacy and safety of exenatide QW was compared to liraglutide 1.8 mg QD in patients with T2DM treatment with lifestyle modification and one or more oral antihyperglycemic agents [10] . Newer GLP-1 RAs (albiglutide, dulaglutide and lixisenatide) have not been compared directly to exenatide QW. In the absence of head-to-head evidence within a clinical trial setting, the efficacy and tolerability of exenatide 2 mg QW, relative to other GLP-1 RAs, can be estimated using both direct and indirect evidence within a network meta-analysis (NMA) [14, 15] Discrepancies between reviewers were resolved as described above.
The Cochrane Collaboration's tool for assessing risk of bias [21] was used to assess the quality of the included RCTs. Two reviewers independently assessed the quality of included studies. A third party resolved disagreement in the manner as described for study selection.
Statistical Methods
Mean values and associated measures of variability [variance, standard deviation, standard error (SE) or confidence interval (CI)] were extracted for continuous endpoints.
Where measures of variability were not reported, the SE was imputed by borrowing information from other studies included in the review, using methods recommended by the Cochrane handbook for systematic reviews of interventions [17] . Counts or proportion of events was extracted for binary endpoints. Meta-regressions were conducted to explore heterogeneity in treatment effects due to differences in baseline values. These models
were not deemed robust, as there were not enough data points informing the covariate effect (i.e., comparisons against the reference treatment informed by more than one study).
The results from these models are hence not presented. Mean changes in HbA 1c , weight, and SBP were analyzed using the mean difference scale; proportion of subjects achieving glycemic target, proportion of subjects experiencing nausea or who discontinued due to adverse events were analyzed on an odds ratio scale. Key elements of patient population and baseline risk were summarized in boxplots, to evaluate heterogeneity in the network [16, 24] . 
Compliance with Ethics Guidelines
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RESULTS

Supporting Evidence
The SLR identified 662 articles of which 14 RCTs met criteria for inclusion in the NMA [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] . A PRISMA flow chart summarizing search results and study selection is provided in the supplementary material ( Figure S1 in the supplementary material). Table 1 89 (20) 126 (14) Sitagliptin 100 mg QD 52 (11) 5 (4) 8.5 ( 1.2) 87 (20) 126 (14) Pioglitazone 45 mg QD 53 (10) 6 (5) 8.5 (1.1)
88 (20) 127 (14) Bolli 
NMA
Characteristics of model fit for all outcomes included in the NMA are presented in the supplementary material (Table S5 ). Ten trials reported the proportion of subjects achieving glycemic target and definitions described as HbA1c \7% and B7% were considered for analysis ( Figure S4 in the supplementary material). There were no statistically significant differences observed for exenatide QW versus the other GLP-1 RAs (Table 3 ).
All 14 included RCTs provided evidence for the network of mean change in weight from baseline ( Figure S5 in the supplementary material). All GLP-1 RA treatment arms were associated with a reduction in weight from reduction against all other GLP-1 RAs in the network, although these comparisons did not achieve statistically significant results (Table 5 ).
A total of 11 RCTs reported nausea as an adverse event, but one trial by Gallwitz et al. (Table 6 ).
Thirteen RCTs reported the number of subjects discontinuing treatment due to adverse events ( Figure S8 in the supplementary material). The endpoint estimate for risk of discontinuation due to adverse events indicated a beneficial effect for exenatide QW compared to dulaglutide 1.5 mg QW, and liraglutide 1.2 mg and 1.8 mg QD, but none of these differences were statistically significant (Table 7) .
Estimates on the absolute scale are presented in the supplementary material (Table S6) .
DISCUSSION
The position statement of the ADA and the EASD recommends the addition of GLP-1 RAs as a therapeutic option for patients with T2DM who are inadequately controlled on metformin monotherapy, with consideration of individual patient-related factors [1] . This study presents the results of an NMA that investigated the relative efficacy and tolerability of GLP-1 RAs, and in particular examined how exenatide QW, Published NMAs on GLP-1 RAs [18, 39, 40] have reported few differences between individual therapies for the outcomes examined [18, 40] . Scott et al., found no statistically significant differences for glycemic control between exenatide QW and liraglutide (1.2 and 1.8 mg) [18] . A recent NMA, presented as a poster, did report that exenatide QW was associated with a greater reduction in HbA1c compared to dulaglutide 1.5 mg QW in the add-on to metformin network, but differences were not statistically significant [39] . In the current study, however, results indicated that exenatide QW was significantly better than lixisenatide 20 lg QD in reducing HbA1c, and comparable to other GLP-1 RAs for change in HbA1c. Another NMA [40] reported that exenatide QW, exenatide 10 mg BID, and liraglutide 1.8 mg QD ranked as the top three agents in terms of weight reduction compared to traditional hypoglycemic agents. In the present NMA, overall change in weight was comparable across all GLP-1 RAs. However, it is important to note that the current study relied upon a different evidence base than previous NMAs, with study duration restricted to 24 ± 6 weeks and the inclusion of any GLP-1 RA at licensed doses.
Based on direct head-to-head trials, researchers have reported significant differences between some GLP-1 RAs. In particular, in the DURATION-1 and DURATION-5 trials, exenatide QW was found to have superior efficacy in HbA1c reduction compared to exenatide BID [8, 9] . In the DURATION-6 trial, the reduction in HbA1c was significantly greater with liraglutide 1.8 mg QD treatment compared to exenatide QW (treatment difference for exenatide minus liraglutide was 0.21%, 95% CI 0.08-0.33) [10] .
Yet, these trials were not included in the present NMA as patients in these trials were on a variety of oral antihyperglycemic agents prior to study entry and continued these throughout the trial, suggesting likely differences in disease severity compared to a population largely on metformin monotherapy.
Real-world evidence of the clinical effectiveness of GLP-1 RAs has been provided by retrospective studies [11] [12] [13] . For change in
HbA1c from baseline, the efficacy has been reported to be comparable between liraglutide QD and exenatide QW [13] , as well as liraglutide QD and exenatide BID [11] . Results of the current NMA also found no differences in HbA1c change between liraglutide QD and exenatide QW. Although HbA1c change between liraglutide QD and exenatide BID was not directly compared, point estimates were similar, particularly for liraglutide 1.2 mg QD and exenatide 10 lg BID. One study has reported liraglutide to be more efficacious than exenatide BID in reducing HbA1c [12] .
However, these studies rely upon the availability of data in medical databases and thus by their study design, may inherently be subject to confounding and bias that is absent from RCTs.
Previous trials have reported that exenatide QW was associated with less frequent mild-to-moderate nausea compared to exenatide BID [8, 9, 41] . In addition, exenatide QW has been previously reported to be associated with fewer treatment discontinuations due to adverse events compared to liraglutide 1.8 mg QD [10] . These findings are in line with the design of exenatide QW, which was developed to provide better tolerability given its gradual titration [42] . However, results in the current study indicated that exenatide QW was comparable to other GLP-1 RAs in the network for both nausea and treatment discontinuation due to AEs. The lack of any significant differences in these results was likely due to the limited evidence base and the low frequency of discontinuation due to AEs in the included trials. Yet, a recent pooled analysis of eight RCTs reported a similar safety and tolerability profile for exenatide QW compared to exenatide BID and liraglutide QD [43] . Results in the current NMA indicated a higher risk of nausea and treatment discontinuation due to AEs with exenatide QW compared to exenatide 5 lg BID, although these differences were not statistically significant. has not been investigated in RCTs. In addition, the current study included an examination of several efficacy and tolerability outcomes.
Strengths and Limitations
Another key strength is the strict inclusion criteria developed for the study. Eligible RCTs were required to include at least 80% of patients who had failed metformin monotherapy prior to study entry, and received a GLP-1 RA as add-on to metformin during the trial. To minimize heterogeneity in the network, there were several trials that did not meet these criteria; in particular, eight exenatide QW trials [8] [9] [10] [44] [45] [46] [47] [48] did not meet these criteria and were therefore excluded from the NMA. In fact, this stringent inclusion/exclusion criteria may have led to the exclusion of treatments that may have formed indirect comparisons to the treatments of interest which could have influenced the results. However, these higher order indirect comparisons would also have contributed less weight to the analysis [49] .
There 
